Objective-To investigate whether the currently recommended age at which to stop cervical screening (64) 
Introduction
The detection and treatment of premalignant conditions by cervical screening programmes reduces both the incidence of and mortality from invasive squamous cancer of the cervix. Cervical cytology screening programmes began haphazardly in Britain from the 1 960s onwards. Different recommendations were made independently for Scotland, England, and Wales,'-3 and there were local variations from one health authority to another in the way that these were implemented. An intercollegiate working party was set up to look particularly at the clinical aspects of the cervical screening programmes and to make recommendations for the United Kingdom as a whole. It reported in November 1987. 4 The fundamental difference recommended was a change from opportunistic screening to a computerised call and recall of women aged 20-64 years. Screening beyond the age of 64 was not considered necessary provided that such women had had three consecutive smear tests with negative results, the most recent one no more than three years previously. The rationale for this was the low incidence of preinvasive disease in older women such as those in Dundee and Angus. ' In 1989 and 1990, 71% and 76% respectively of all the women aged between 20 and 59 in Tayside, Scotland, had been screened at least once within the previous five years. Women were excluded from screening for reasons such as hysterectomy (about 7%), virginity, terminal disease, etc. The true coverage of cervical screening by the end of 1990 for the Tayside region was therefore estimated to be well over 80% of women between 20 and 60. Table I shows the percentage of women in the region who were never screened. The districts of Dundee and Angus, part of Tayside region, have a total population of women between 16 and 59 of around 167 000 (1991 census) . From this population over 57000 smears were taken during the two years of our study. The cytopathology laboratory serving Dundee and Angus was among the first to complete computerised call of the local population. This gave us the opportunity to re-examine the incidence of cervical intraepithelial neoplasia to determine whether it might be feasible to stop screening at an earlier age. As well as having benefits, health screening also has disadvantages-for example, inducing needless anxiety in people who do not have the disease in question and no significant prospect of developing it. In addition, there is clearly a need to use health service resources as cost effectively as possible. Identifying a group of women who no longer benefit from cervical screening is therefore an attractive proposition. negative results at four to five year intervals with the most recent at least three years before the index smear. P5, prevalent disease-two or more smear tests at four to five year intervals with the most recent at least three years before the index smear and at least one of these having given abnormal results.
?I5, incident disease-cases not strictly fulfilling category I5 but on analysis seeming to be incident disease.
?P5, prevalent disease-cases not strictly fulfilling category P5 but on analysis seeming to be prevalent disease.
The data were analysed with these various categories. The denominators were the numbers of smears taken between 1 January 1989 and 31 December 1990 in the corresponding age groups. We could not separate out women who had had more than one smear taken during this time. There would, however, have been few such women. Those with more than one smear taken would most likely have been followed up after treatment for cervical intraepithelial neoplasia and, according to protocol, would have had no more than three smears taken over the two year period. Most of these women (about 80%) would have been younger than 35. Very few women would have had more than two abnormal results as two borderline or mildly dyskaryotic results automatically qualify a women for colposcopy. These women would also have been mainly in the younger age groups. Our aim was to determine whether continuation of cervical screening is necessary in older women with a history of consistently negative results. Analysis of the data was concentrated on them and so we do not think that the results in the older age groups are invalidated by using numbers of smear tests as the denominator.
Results Table II shows the number of women diagnosed as having cervical neoplasia in the two years of the study compared with the number of smears taken in the corresponding age groups. Similar numbers of smears were taken in women aged between 31 and 45 and in women aged up to 30, but cervical intraepithelial neoplasia was much commoner in the younger group. Table III shows the number of smears taken per case detected. Grade III disease is more commonly diagnosed than grade II disease, which is more commonly diagnosed than grade I disease. The frequency with which cervical intraepithelial neoplasia grades II and III are detected declines with age whereas the decline in the detection of grade I disease is apparently arrested temporarily in the fifth decade. The decline in cervical intraepithelial neoplasia grade III is slower than the decline in grade II disease, which is slower than the decline in grade I disease. About 98% of all cases (733 of 749) were found in women aged 50 or younger. Figure 1 shows the number of cases detected for each 10 000 smears taken.
In tables IV and V the data were further analysed for women over the age of 40 by comparing the number of cases of cervical intraepithelial neoplasia and microinvasive and invasive neoplasia detected 
The position is different for older women who have participated in the screening programme. Women over the age of 65 accounted for only 1-4% (108 of 7813) of new cases of carcinoma in situ of the cervix registered in England and Wales in 1984,9 and women over the age of 50 accounted for only 7-8% (607 of 7813). The generally accepted explanation for this is that most screening is carried out in younger women, who therefore account for most cases of premalignancy.9 Our data clearly show that this explanation is incomplete. By determining the number of smear tests carried out for each age group we have shown a distinct increase in the number of smears required to be taken for each case of cervical intraepithelial neoplasia detected with increasing age for all grades.
A prerequisite of any public health screening programme is that the condition sought must be reasonably common in the target population. A population subjected to screening should therefore be examined to determine those at low risk who stand to gain little from the screening process. Women living in Dundee and Angus have participated in a cervical screening programme since 1962. This programme has been associated with a considerable reduction in the incidence of and mortality from cervical cancer. 5 We have long suspected that cervical intraepithelial neoplasia is a condition which develops predominantly in young women. Left undetected most cases probably regress spontaneously but some persist. Invasive cancer may develop after a variable period depending on various factors possibly involving a relaxation of immunocompetence. Persistent cervical intraepithelial neoplasia may be detected sooner or later depending on the frequency, adequacy, and correct interpretation of the smears taken. Our data show that it is extremely uncommon for cervical intraepithelial neoplasia to develop de novo in older women.
Once the existence of cervical intraepitheliai neoplasia can be confidently excluded the woman can be reassured and released from the screening programme. Currently this is the recommendation for women aged 64 provided that they have had three consecutive negative results, the most recent one no more than three years previously. Our data suggest that the age at which this applies could be lowered to 50. In the Dundee BMJ VOLUME 306earlier, around 1941. A similar birth cohort effect is seen in incidence.8 There is little evidence for this particular effect in our study perhaps because Scottish women are less at risk than their English and Welsh contemporaries or perhaps because the risk can be largely negated by an effective screening programme.
Women reaching the age of 50 may welcome release from the cervical screening programme as they embark on the breast screening programme. It is not known whether the increasing uptake of hormone replacement therapy will maintain the higher incidence of cervical intraepithelial neoplasia seen in younger women by rejuvenating the cervix and a prospective randomised trial would be warranted.
Patients, methods, and results
The recruitment method was described previously.2 Polyribosylribitol phosphate-tetanus and diphtheriapertussis-tetanus immunisations were given separately by intramuscular injection at 2, 3, and 4 months. Venous blood was obtained for serological examination at 2 months, 5 months, and, in 95 infants, 1 year.
The concentration of total IgG antibody to polyribosylribitol phosphate was measured by enzyme linked immunosorbent assay (ELISA). Each sample taken at 1 year was assayed on the same plate as a previously collected sample from the same infant. The lower limit of sensitivity of the assay was 0-16 ,ug/ml. Values below this were arbitrarily assigned the value 0-08 ,ug/ml for calculation of geometric mean titres.
At 1 year 89 infants had a serum polyribosylribitol phosphate antibody concentration >0-15 pLg/ml (figure) . In 43 the concentration was > 1-0 pLg/ml. The geometric mean titre was 0-83 pLg/ml. the antibody concentrations measured at 5 months of age five infants showed at least a twofold rise and two of these showed more than fourfold rises at 1 year. None had clinical disease. One infant did not respond to primary immunisation (antibody concentration <0-16 pLg/ml at 5 months). A booster dose of the vaccine was given at 16 months, and one month later the antibody concentration was 3-4 pLg/ml.
Comment
We found that nearly all 1 year old infants immunised with polyribosylribitol phosphate-tetanus at 2, 3, and 4 months of age had serum antibody concentrations that are likely to be protective (>0-15 ,ug/ml). Without immunisation nearly all children of this age have antibody concentrations below 0-15 p.g/ml despite likely exposure to H influenzae type b.3 The infant who failed to respond to primary immunisation was tested for immunodeficiency, but none was found and she responded well to a booster dose.
Immunisation of older infants-for example, according to the previous British schedule at ages 3, 5, and 9 months-produces higher antibody concentrations3 and therefore prolongs protection if indeed prevention of disease depends on concentrations being maintained above a threshold. A booster in the second year of life is recommended in most countries with routine immunisation against H influenzae type b. Our findings suggest that this may not be necessary.
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